Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2016 1
2017 3
2018 3
2019 5
2020 2
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells.
Hamaidi I, Zhang L, Kim N, Wang MH, Iclozan C, Fang B, Liu M, Koomen JM, Berglund AE, Yoder SJ, Yao J, Engelman RW, Creelan BC, Conejo-Garcia JR, Antonia SJ, Mulé JJ, Kim S. Hamaidi I, et al. Among authors: creelan bc. Cell Metab. 2020 Sep 1;32(3):420-436.e12. doi: 10.1016/j.cmet.2020.07.008. Epub 2020 Aug 7. Cell Metab. 2020. PMID: 32768387 Free PMC article.
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, Antonia SJ, Shafique MR, Ugrenovic-Petrovic M, Sansil S, Neuger A, Ozakinci H, Boyle TA, Kim J, Haura EB, Gray JE. Saltos AN, et al. Among authors: creelan bc. Lung Cancer. 2023 Sep;183:107313. doi: 10.1016/j.lungcan.2023.107313. Epub 2023 Jul 22. Lung Cancer. 2023. PMID: 37499521 Clinical Trial.
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management.
Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration. Girotra M, et al. Among authors: creelan bc. JNCI Cancer Spectr. 2018 Jul;2(3):pky021. doi: 10.1093/jncics/pky021. Epub 2018 Jul 19. JNCI Cancer Spectr. 2018. PMID: 30057972 Free PMC article. Review.
Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer.
Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Gordian E, et al. Among authors: creelan bc. Oncotarget. 2021 Jun 22;12(13):1325. doi: 10.18632/oncotarget.28004. eCollection 2021 Jun 22. Oncotarget. 2021. PMID: 34194632 Free PMC article.
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.
Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ. Chiappori AA, et al. Among authors: creelan bc. Cancer Immunol Immunother. 2019 Mar;68(3):517-527. doi: 10.1007/s00262-018-2287-9. Epub 2018 Dec 27. Cancer Immunol Immunother. 2019. PMID: 30591959 Free PMC article. Clinical Trial.
18 results